EIF4EBP2

Across TCGA pan-cancer cohorts, EIF4EBP2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated EIF4EBP2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher EIF4EBP2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated EIF4EBP2 expression acts as an unfavorable survival marker, although some lineages such as PDAC and OV show a favorable association.

PDAC, OV, and CCRCC are the cancer types where EIF4EBP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	All	0.881	0.719	.003	28	view →
OV	DFS	Tertile	All	0.896	0.466	.026	8	view →
CCRCC	DFS	Tertile	All	1.000	0.927	.017	8	view →
COAD	DFS	Median	III,IV	0.811	1.000	.034	6	view →
LSCC	DFS	Median	II,III,IV	0.866	0.963	.040	6	view →
GBM	OS	Quartile	All	0.190	0.586	.049	2	view →
HNSC	DFS	Median	IV	1.000	0.927	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

EIF4EBP2–PDAC (DFS)

Open the PDAC breakdown →